<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Sci Rep</journal-id><journal-id journal-id-type="iso-abbrev">Sci Rep</journal-id><journal-id journal-id-type="pmc-domain-id">1579</journal-id><journal-id journal-id-type="pmc-domain">scirep</journal-id><journal-title-group><journal-title>Scientific Reports</journal-title></journal-title-group><issn pub-type="epub">2045-2322</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11282182</article-id><article-id pub-id-type="pmcid-ver">PMC11282182.1</article-id><article-id pub-id-type="pmcaid">11282182</article-id><article-id pub-id-type="pmcaiid">11282182</article-id><article-id pub-id-type="pmid">39060397</article-id><article-id pub-id-type="doi">10.1038/s41598-024-67859-0</article-id><article-id pub-id-type="publisher-id">67859</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Prognostic factors for esophageal respiratory fistula in unresectable esophageal squamous cell carcinoma treated with radiotherapy</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name name-style="western"><surname>Qi</surname><given-names initials="JC">Jia-Chao</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name name-style="western"><surname>Zhi</surname><given-names initials="L">Lijia</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Li</surname><given-names initials="H">Huangyu</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Huang</surname><given-names initials="Y">Yanping</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ye</surname><given-names initials="Y">Yuming</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Li</surname><given-names initials="H">Hao</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wang</surname><given-names initials="T">Tiezhu</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Lin</surname><given-names initials="L">Li</given-names></name><address><email>88385785@qq.com</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Zhuang</surname><given-names initials="Y">Yuezhen</given-names></name><address><email>18859669000@163.com</email></address><xref ref-type="aff" rid="Aff3">3</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="GRID">grid.256112.3</institution-id><institution-id institution-id-type="ISNI">0000 0004 1797 9307</institution-id><institution>Department of Respiratory and Critical Care Medicine, </institution><institution>Zhangzhou Affiliated Hospital of Fujian Medical University, </institution></institution-wrap>No. 59, Shengli Rd, Xiangcheng District, Zhangzhou, 363000 Fujian People&#8217;s Republic of China </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00pcrz470</institution-id><institution-id institution-id-type="GRID">grid.411304.3</institution-id><institution-id institution-id-type="ISNI">0000 0001 0376 205X</institution-id><institution>Department of Intensive Care Unit, </institution><institution>Hospital of Chengdu University of Traditional Chinese Medicine, </institution></institution-wrap>No. 39, Twelve Bridges Rd, Jinniu District, Chengdu, 610075 Sichuan People&#8217;s Republic of China </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/050s6ns64</institution-id><institution-id institution-id-type="GRID">grid.256112.3</institution-id><institution-id institution-id-type="ISNI">0000 0004 1797 9307</institution-id><institution>Department of Gynecology, </institution><institution>Zhangzhou Affiliated Hospital of Fujian Medical University, </institution></institution-wrap>No. 59, Shengli Rd., Xiangcheng District, Zhangzhou, 363000 Fujian People&#8217;s Republic of China </aff></contrib-group><pub-date pub-type="epub"><day>26</day><month>7</month><year>2024</year></pub-date><pub-date pub-type="collection"><year>2024</year></pub-date><volume>14</volume><issue-id pub-id-type="pmc-issue-id">452196</issue-id><elocation-id>17144</elocation-id><history><date date-type="received"><day>26</day><month>3</month><year>2024</year></date><date date-type="accepted"><day>16</day><month>7</month><year>2024</year></date></history><pub-history><event event-type="pmc-release"><date><day>26</day><month>07</month><year>2024</year></date></event><event event-type="pmc-live"><date><day>27</day><month>07</month><year>2024</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-07-28 09:25:21.137"><day>28</day><month>07</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2024</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article&#8217;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#8217;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="41598_2024_Article_67859.pdf"/><abstract id="Abs1"><p id="Par1">Limited studies have focused on the prognostic factors of esophageal respiratory fistula (ERF) associated with radiotherapy in patients with unresectable esophageal squamous cell carcinoma (ESCC). Between January 1st, 2014 and January 1st, 2021, we included patients who were initially diagnosed with unresectable ESCC and underwent radiotherapy. All patients were followed up for a period of 2&#160;years after completing their radiotherapy treatment. The primary outcomes of the study were defined as death or severe adverse events. The survival curves of ERF were calculated using the Kaplan&#8211;Meier method. Cox proportional hazards model was employed to calculated the prognostic factors. A cohort of 232 patients underwent radiotherapy, of whom 32 patients experienced ERF. The median period from initial diagnosis of ESCC to ERF was 5.75&#160;months, and the median period from ERF to the primary outcome was 4.6&#160;weeks. Neck&#8201;+&#8201;upper chest location (odds ratio [OR] 3.305), high T stage (OR 1.765), esophageal stenosis (OR&#8201;1.073), high neutrophil to lymphocyte ratio (NLR) (OR 1.384) and platelet to lymphocyte ratio (PLR) (OR 1.765) were risk factors for the occurrence of ERF. Cox regression analysis suggested that tumor location (hazards ratio [HR] 3.572, 95% confidence interval [CI] 2.467&#8211;5.1), high T stage (HR 4.050, 95% CI 2.812&#8211;5.831), esophageal stenosis (HR 2.643, 95% CI 1.753&#8211;3.983), high PLR (HR 2.541, 95% CI 1.868&#8211;3.177) were independent prognostic factors for poor survival. Esophageal stenosis, neck&#8201;+&#8201;upper chest tumor location, high T stage and PLR predicted the prognosis of ERF in ESCC patients undergoing radiotherapy.</p></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Prognostic factors</kwd><kwd>Esophageal respiratory fistula</kwd><kwd>Unresectable esophageal squamous cell carcinoma</kwd><kwd>Radiotherapy</kwd></kwd-group><kwd-group kwd-group-type="npg-subject"><title>Subject terms</title><kwd>Lung cancer</kwd><kwd>Medical research</kwd></kwd-group><funding-group><award-group><funding-source><institution>Grade A for scientific research of Zhangzhou Affiliated Hospital of Fujian Medical University</institution></funding-source><award-id>PDA202203</award-id><principal-award-recipient><name name-style="western"><surname>Qi</surname><given-names>Jia-Chao</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution>Natural Science Foundation of Fujian Province</institution></funding-source><award-id>2023J01122413</award-id><principal-award-recipient><name name-style="western"><surname>Qi</surname><given-names>Jia-Chao</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution>Natural Science Foundation of Zhangzhou</institution></funding-source><award-id>ZZ2023J19</award-id><principal-award-recipient><name name-style="western"><surname>Qi</surname><given-names>Jia-Chao</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; Springer Nature Limited 2024</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par14">Esophageal squamous cell carcinoma (ESCC) poses a significant health threat with a high incidence particularly among disadvantaged populations<sup><xref ref-type="bibr" rid="CR1">1</xref></sup>. Owing to a lack of early screening, over 70% of localized ESCC cases diagnosed at an advanced stage missed the possibility of radical surgery<sup><xref ref-type="bibr" rid="CR2">2</xref></sup>. For these people, chemoradiotherapy was recognized as the standard approach for treating ESCC without distant metastasis<sup><xref ref-type="bibr" rid="CR3">3</xref></sup>.</p><p id="Par15">Despite the improvements in local control and long-term survival rates of ESCC, radiotherapy was associated with a relatively high incidence of esophageal fistula (EF)<sup><xref ref-type="bibr" rid="CR4">4</xref></sup>. To our knowledge, an incidence of 20&#8211;30% of tracheobronchial invasion by ESCC occasionally led to esophageal respiratory fistula (ERF) during or after radiotherapy<sup><xref ref-type="bibr" rid="CR5">5</xref></sup>. Kinsman also highlighted that radiotherapy can induce esophageal inflammation and tumor necrosis, which may increase the risk of early ERF formation<sup><xref ref-type="bibr" rid="CR6">6</xref></sup>. A meta-analysis has revealed that the median survival time of patients with ESCC who develop EF following radiotherapy is significantly shortened by approximately 3.6&#160;months<sup><xref ref-type="bibr" rid="CR7">7</xref></sup>. In the absence of appropriate treatment, fistulae can lead to pneumonia, lung abscess, and eventually sepsis or acute respiratory distress syndrome<sup><xref ref-type="bibr" rid="CR8">8</xref></sup>.</p><p id="Par16">Studies have been conducted on the analysis of risk factors of EF treated with chemoradiotherapy<sup><xref ref-type="bibr" rid="CR4">4</xref></sup> and radiotherapy<sup><xref ref-type="bibr" rid="CR9">9</xref></sup>. Limited studies have focused on the prognosis factors of ERF after radiotherapy. Patients with proximal squamous cell carcinoma (SCC) of the esophagus and smoking history, as well as young patients with SCC, should be closely monitored for the development of ERF. However, they only studied the risk factors and they did not focus on the impact of radiotherapy<sup><xref ref-type="bibr" rid="CR7">7</xref></sup>. Besides, data has shown that advanced disease stage, invasion of upper-mid thoracic esophagus, length of primary tumor, and esophageal stenosis are all associated with the onset of ERF<sup><xref ref-type="bibr" rid="CR4">4</xref></sup>. Further, Zhang et al. prospectively evaluated the risk factors associated with fistula formation in patients with ESCC receiving chemoradiotherapy. They showed that esophageal stenosis, T4 stage, and high levels of carcinoembryonic antigen (CEA) were related with EF<sup><xref ref-type="bibr" rid="CR10">10</xref></sup>.</p><p id="Par17">The purpose of this study is to identify the prognostic factors associated with ERF after radiotherapy and the outcomes of ERF in order to optimize patient selection and ultimately improve quality of life (QoL).</p></sec><sec id="Sec2"><title>Methods</title><sec id="Sec3"><title>Materials and methods study selection</title><p id="Par18">This study enrolled patients who were initially diagnosed with ESCC between January 1st, 2014 and January 1st, 2021. The inclusion criteria were as follows: age ranged from 18 to 75&#160;years, pathologically confirmed ESCC, staged II&#8211;III based on the 7th edition of the American Joint Committee on Cancer TNM staging system, treated by radiotherapy with or without chemotherapy, and Karnofsky performance status (KPS)&#8201;&gt;&#8201;70. Patients with the following criteria were excluded: (1) concomitant secondary malignancy; (2) ERF was present before radiotherapy; (3) imaging or bronchoscopy confirmed ERF secondary to tumor recurrence; (4) history of cardiothoracic surgery within 3&#160;months prior to ERF; (5) lost to follow-up. This study was approved by the Institutional Review Board of the Zhangzhou affiliated Hospital of Fujian Medical University, and written informed consent was obtained from each patient.</p></sec><sec id="Sec4"><title>Data collection</title><p id="Par19">Data collection included demographics such as body mass index (BMI), KPS, smoking and alcohol history, concomitant disease, TNM stage, tumor location, grading of esophageal stenosis, history of chemotherapy, split dose of radiotherapy, radiotherapy mode (synchronous/sequential), the modalities administered on the patient to treat cancer, radiotherapy-related adverse events, and the date of last time follow-up and laboratory findings.</p><p id="Par20">Lost to follow up in our study<sup><xref ref-type="bibr" rid="CR11">11</xref></sup> was defined as patients who attended appointments during the study period (1 or more) with no additional visits after&#8201;&gt;&#8201;6 months. ERF was diagnosed when barium leakage was observed on esophagography or a fistula was apparent on endoscopy or bronchoscopy. Endoscopically measured luminal stenosis was determined based on the following scale: I, none stenosis or minimal stricture without resistance while passing endoscope; II, significant stenosis allowing endoscopic passage with remarkable resistance or severe stenosis preventing passage of the endoscope through the tumor site<sup><xref ref-type="bibr" rid="CR12">12</xref></sup>.</p></sec><sec id="Sec5"><title>Radiotherapy</title><p id="Par21">All patients with ESCC in our study underwent either concurrent chemoradiotherapy (CRT), sequential CRT, or radiotherapy alone. During treatment, patients were placed in a supine position and equipped with a body vacuum bag or head and neck thermoplastics to minimize movement. Computerized tomography (CT) images were acquired from the ring membrane to the lower edge of the lungs at a slice thickness of 3.0&#160;mm. These images were then transferred to the Varian Eclipse 8.6.15 planning system for target delineation and planning. Gross tumor volume (GTV), clinical target volume (CTV), and planned target volume (PTV) were defined on the CT images. GTV encompassed all visible tumors and metastatic lymph nodes on CT/PET-CT/MRI scans. CTV included subclinical lesions and high-risk lymphatic drainage areas within GTV<sup><xref ref-type="bibr" rid="CR13">13</xref></sup>. The PTV was defined as a zone extending 0.5&#8211;0.8&#160;cm beyond the CTV. Radiation therapy was administered using a 6 MV X-ray, with most doses delivered as 1.8&#8211;2.5&#160;Gy (five times a week). To minimize radiation damage to vital structures, maximum doses of radiation from the spinal cord, heart, and lungs were set at 45&#160;Gy, 30&#160;Gy and 20&#160;Gy, respectively<sup><xref ref-type="bibr" rid="CR14">14</xref></sup>.</p></sec><sec id="Sec6"><title>Follow-up</title><p id="Par22">All patients were followed up for a total of 2&#160;years after radiotherapy. During the first year, follow-up visits were conducted every 2&#160;months unless there were emergent symptoms requiring immediate medical intervention. At each follow-up visit, a history of taking and radiographic examinations was performed, including an esophagus barium meal examination and contrast-enhanced CT scans of the cervical region, chest, and abdomen.</p></sec><sec id="Sec7"><title>Study outcomes</title><p id="Par23">The primary outcome of the study was defined as death or severe adverse events of ERF such as severe pneumonia<sup><xref ref-type="bibr" rid="CR15">15</xref></sup> and lung disease. Lung disease particularly indicates massive hemoptysis. The definition of massive hemoptysis has focused on the volume of blood lost per hour and per day, which was 300&#160;mL to 600&#160;mL per 24&#160;h or 3 episodes of hemoptysis in 1&#160;week<sup><xref ref-type="bibr" rid="CR16">16</xref></sup>. As long as any of these events was achieved, we identified that the outcome of the study is reached. The length of survival was determined by the interval in months between radiotherapy and the date of death, as well as the occurrence of serious adverse events or loss of follow-up.</p></sec><sec id="Sec8"><title>Statistical analysis</title><p id="Par24">SPSS 24.0 was used for statistical analysis. Univariate Chi-square/Fisher test was performed for the influencing factors. In the logistic regression analysis to predict ERF, multivariate analysis was performed using stepwise selection (likelihood ratio) for factors that showed significant differences (p&#8201;&lt;&#8201;0.05) in the univariate analysis. And the survival curves of ERF were calculated by the Kaplan&#8211;Meier method. The Cox proportional hazards model was performed to calculated the prognostic factors. And p-value&#8201;&lt;&#8201;0.05 was recognized as statistically significant in all analyses.</p></sec><sec id="Sec9"><title>Ethics approval and consent to participate</title><p id="Par25">All procedures performed in the study involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The study was approved by the ethical committee of Zhangzhou Affiliated Hospital of Fujian Medical University. All patients provided informed written consent before the study.</p></sec></sec><sec id="Sec10"><title>Results</title><sec id="Sec11"><title>Patient and disease characteristics</title><p id="Par26">A total of 232 patients were eventually included. All patients were treated with radiotherapy (149 received concurrent modality and 83 received sequential modality). Thirty-two patients (13.8%) developed ERF. The median ages were 61&#160;years (range 43&#8211;75&#160;years) and 63&#160;years (range 17&#8211;90&#160;years) for patients with or without ERF, respectively. And the percentage of ERF patients diagnosed by barium swallow study versus visual inspection was 62.5% (barium swallow purely) vs 46.87% (visual inspection). The patients with ERF presented with a more advanced stage initially. The incidence of tumor located in the neck&#8201;+&#8201;upper thoracic segment was higher to develop ERF. The detailed information was shown in Table <xref rid="Tab1" ref-type="table">1</xref>.<table-wrap id="Tab1" position="float" orientation="portrait"><label>Table 1</label><caption><p>Clinical characteristics of patients between ERF group and non-ERF group.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Characteristic</th><th align="left" colspan="1" rowspan="1">ERF (n&#8201;=&#8201;32)</th><th align="left" colspan="1" rowspan="1">Non-ERF group (n&#8201;=&#8201;200)</th><th align="left" colspan="1" rowspan="1">&#967;<sup>2</sup> value</th><th align="left" colspan="1" rowspan="1">p value</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Sex, male</td><td char="." align="char" colspan="1" rowspan="1">23</td><td char="." align="char" colspan="1" rowspan="1">160</td><td char="." align="char" colspan="1" rowspan="1">0.972</td><td char="." align="char" colspan="1" rowspan="1">0.324</td></tr><tr><td align="left" colspan="1" rowspan="1">Age&#8201;&gt;&#8201;60&#160;years</td><td char="." align="char" colspan="1" rowspan="1">15</td><td char="." align="char" colspan="1" rowspan="1">124</td><td char="." align="char" colspan="1" rowspan="1">1.903</td><td char="." align="char" colspan="1" rowspan="1">0.168</td></tr><tr><td align="left" colspan="1" rowspan="1">KPS score&#8201;&#8804;&#8201;80</td><td char="." align="char" colspan="1" rowspan="1">5</td><td char="." align="char" colspan="1" rowspan="1">64</td><td char="." align="char" colspan="1" rowspan="1">5.386</td><td char="." align="char" colspan="1" rowspan="1">0.124</td></tr><tr><td align="left" colspan="1" rowspan="1">BMI&#8201;&#8804;&#8201;18.5</td><td char="." align="char" colspan="1" rowspan="1">12</td><td char="." align="char" colspan="1" rowspan="1">60</td><td char="." align="char" colspan="1" rowspan="1">1.126</td><td char="." align="char" colspan="1" rowspan="1">0.289</td></tr><tr><td align="left" colspan="1" rowspan="1">Smoking history</td><td char="." align="char" colspan="1" rowspan="1">14</td><td char="." align="char" colspan="1" rowspan="1">92</td><td char="." align="char" colspan="1" rowspan="1">0.308</td><td char="." align="char" colspan="1" rowspan="1">0.579</td></tr><tr><td align="left" colspan="1" rowspan="1">Alcohol history</td><td char="." align="char" colspan="1" rowspan="1">8</td><td char="." align="char" colspan="1" rowspan="1">16</td><td char="." align="char" colspan="1" rowspan="1">6.117</td><td char="." align="char" colspan="1" rowspan="1">0.018</td></tr><tr><td align="left" colspan="1" rowspan="1">Hypertension</td><td char="." align="char" colspan="1" rowspan="1">7</td><td char="." align="char" colspan="1" rowspan="1">56</td><td char="." align="char" colspan="1" rowspan="1">0.361</td><td char="." align="char" colspan="1" rowspan="1">0.548</td></tr><tr><td align="left" colspan="1" rowspan="1">Diabetes</td><td char="." align="char" colspan="1" rowspan="1">2</td><td char="." align="char" colspan="1" rowspan="1">12</td><td char="." align="char" colspan="1" rowspan="1">0.023</td><td char="." align="char" colspan="1" rowspan="1">1.000</td></tr><tr><td align="left" colspan="1" rowspan="1">Ulcerative tumor</td><td char="." align="char" colspan="1" rowspan="1">4</td><td char="." align="char" colspan="1" rowspan="1">20</td><td char="." align="char" colspan="1" rowspan="1">0.282</td><td char="." align="char" colspan="1" rowspan="1">0.595</td></tr><tr><td align="left" colspan="1" rowspan="1">Esophageal stenosis</td><td char="." align="char" colspan="1" rowspan="1">14</td><td char="." align="char" colspan="1" rowspan="1">24</td><td char="." align="char" colspan="1" rowspan="1">12.629</td><td char="." align="char" colspan="1" rowspan="1">0.000</td></tr><tr><td align="left" colspan="1" rowspan="1">Airway stenting</td><td char="." align="char" colspan="1" rowspan="1">4</td><td char="." align="char" colspan="1" rowspan="1">8</td><td char="." align="char" colspan="1" rowspan="1">2.737</td><td char="." align="char" colspan="1" rowspan="1">0.143</td></tr><tr><td align="left" colspan="1" rowspan="1">Neck&#8201;+&#8201;upper chest Tumor location</td><td char="." align="char" colspan="1" rowspan="1">14</td><td char="." align="char" colspan="1" rowspan="1">44</td><td char="." align="char" colspan="1" rowspan="1">6.553</td><td char="." align="char" colspan="1" rowspan="1">0.010</td></tr><tr><td align="left" colspan="1" rowspan="1">High T stage (T4)</td><td char="." align="char" colspan="1" rowspan="1">15</td><td char="." align="char" colspan="1" rowspan="1">48</td><td char="." align="char" colspan="1" rowspan="1">9.974</td><td char="." align="char" colspan="1" rowspan="1">0.002</td></tr><tr><td align="left" colspan="1" rowspan="1">High N stage (N3)</td><td char="." align="char" colspan="1" rowspan="1">6</td><td char="." align="char" colspan="1" rowspan="1">44</td><td char="." align="char" colspan="1" rowspan="1">0.040</td><td char="." align="char" colspan="1" rowspan="1">0.841</td></tr><tr><td align="left" colspan="1" rowspan="1">Synchronous chemotherapy</td><td char="." align="char" colspan="1" rowspan="1">25</td><td char="." align="char" colspan="1" rowspan="1">124</td><td char="." align="char" colspan="1" rowspan="1">5.823</td><td char="." align="char" colspan="1" rowspan="1">0.016</td></tr><tr><td align="left" colspan="1" rowspan="1">Split dose of radiotherapy (&gt;&#8201;2&#160;Gy)</td><td char="." align="char" colspan="1" rowspan="1">16</td><td char="." align="char" colspan="1" rowspan="1">76</td><td char="." align="char" colspan="1" rowspan="1">6.670</td><td char="." align="char" colspan="1" rowspan="1">0.010</td></tr><tr><td align="left" colspan="1" rowspan="1">Radiation esophagitis</td><td char="." align="char" colspan="1" rowspan="1">3</td><td char="." align="char" colspan="1" rowspan="1">56</td><td char="." align="char" colspan="1" rowspan="1">5.410</td><td char="." align="char" colspan="1" rowspan="1">0.035</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;NLR (&gt;&#8201;1.78)</td><td char="." align="char" colspan="1" rowspan="1">23</td><td char="." align="char" colspan="1" rowspan="1">120</td><td char="." align="char" colspan="1" rowspan="1">3.920</td><td char="." align="char" colspan="1" rowspan="1">0.048</td></tr><tr><td align="left" colspan="1" rowspan="1">PLR (&gt;&#8201;131.28)</td><td char="." align="char" colspan="1" rowspan="1">22</td><td char="." align="char" colspan="1" rowspan="1">110</td><td char="." align="char" colspan="1" rowspan="1">4.218</td><td char="." align="char" colspan="1" rowspan="1">0.040</td></tr></tbody></table><table-wrap-foot><p><italic toggle="yes">ERF</italic> esophageal respiratory fistula, <italic toggle="yes">PLR</italic> platelet to lymphocyte ratio, <italic toggle="yes">NLR</italic> neutrophil to lymphocyte ratio, <italic toggle="yes">BMI</italic> body mass index, <italic toggle="yes">KPS</italic> Karnofsky performance status.</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec12"><title>Follow-up</title><p id="Par27">The median period from initial diagnosis of ESCC to ERF was 5.75&#160;months (range 0.6&#8211;8&#160;months) after radiotherapy. And the median period from initial diagnosis of ERF to the outcome of the study was 4.6&#160;weeks (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>). The median follow-up period was 23.2&#160;months (range 22.6&#8211;23.7&#160;months) after radiotherapy in control group. Nine of thirty-two patients who developed ERF experienced fistula during treatment, while the other 23 patients developed fistula after the completion of chemoradiotherapy.<fig id="Fig1" position="float" orientation="portrait"><label>Figure 1</label><caption><p>Kaplan&#8211;Meier estimates of the overall survival in patients categorized by the occurrence of ERF. The length of survival was determined by the interval in months between radiotherapy and the date of death, as well as the occurrence of serious adverse events or loss of follow-up.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO1" position="float" orientation="portrait" xlink:href="41598_2024_67859_Fig1_HTML.jpg"/></fig></p></sec><sec id="Sec13"><title>Logistic regression analysis of risk factors for the development of ERF</title><p id="Par28">Among the parameters, esophageal stenosis, neck&#8201;+&#8201;upper chest tumor location, T stage, history of chemotherapy, fraction dose of radiotherapy, radiation esophagitis, high NLR and PLR were evaluated as the significant risk factors for ERF in ESCC patients undergoing radiotherapy (Table <xref rid="Tab2" ref-type="table">2</xref>). Further multivariate analysis showed that tumor location, high T stage, esophageal stenosis, high NLR and PLR were the independent risk factors for ERF after adjusting for confounders (odds ratio [OR] 3.305, <italic toggle="yes">p</italic>&#8201;=&#8201;0.039; OR 1.765, <italic toggle="yes">p</italic>&#8201;=&#8201;0.002; OR 1.073, <italic toggle="yes">p</italic>&#8201;=&#8201;0.005, OR 1.384, <italic toggle="yes">p</italic>&#8201;=&#8201;0.000, OR 1.765, <italic toggle="yes">p</italic>&#8201;=&#8201;0.000, respectively) (Table <xref rid="Tab3" ref-type="table">3</xref>).<table-wrap id="Tab2" position="float" orientation="portrait"><label>Table 2</label><caption><p>Univariate logistic regression analysis of risk factors of ERF after radiotherapy for ESCC.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Parameters</th><th align="left" colspan="1" rowspan="1">OR</th><th align="left" colspan="1" rowspan="1">p value</th><th align="left" colspan="1" rowspan="1">95% CI</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Alcohol history</td><td char="." align="char" colspan="1" rowspan="1">1.831</td><td char="." align="char" colspan="1" rowspan="1">0.003</td><td align="left" colspan="1" rowspan="1">1.037&#8211;1.918</td></tr><tr><td align="left" colspan="1" rowspan="1"><p>Tumor location</p><p>Neck&#8201;+&#8201;upper chest</p></td><td char="." align="char" colspan="1" rowspan="1">3.825</td><td char="." align="char" colspan="1" rowspan="1">0.039</td><td align="left" colspan="1" rowspan="1">1.184&#8211;11.236</td></tr><tr><td align="left" colspan="1" rowspan="1">T stage (T4)</td><td char="." align="char" colspan="1" rowspan="1">1.953</td><td char="." align="char" colspan="1" rowspan="1">0.001</td><td align="left" colspan="1" rowspan="1">1.137&#8211;2.115</td></tr><tr><td align="left" colspan="1" rowspan="1">Synchronous chemotherapy</td><td char="." align="char" colspan="1" rowspan="1">1.424</td><td char="." align="char" colspan="1" rowspan="1">0.047</td><td align="left" colspan="1" rowspan="1">1.139&#8211;1.851</td></tr><tr><td align="left" colspan="1" rowspan="1">Split dose of radiotherapy (&gt;&#8201;2&#160;Gy)</td><td char="." align="char" colspan="1" rowspan="1">1.772</td><td char="." align="char" colspan="1" rowspan="1">0.025</td><td align="left" colspan="1" rowspan="1">1.311&#8211;1.994</td></tr><tr><td align="left" colspan="1" rowspan="1">Esophageal stenosis</td><td char="." align="char" colspan="1" rowspan="1">1.273</td><td char="." align="char" colspan="1" rowspan="1">0.004</td><td align="left" colspan="1" rowspan="1">1.149&#8211;1.585</td></tr><tr><td align="left" colspan="1" rowspan="1">Radiation esophagitis</td><td char="." align="char" colspan="1" rowspan="1">3.024</td><td char="." align="char" colspan="1" rowspan="1">0.014</td><td align="left" colspan="1" rowspan="1">2.622&#8211;13.148</td></tr><tr><td align="left" colspan="1" rowspan="1">NLR (&gt;&#8201;1.78)</td><td char="." align="char" colspan="1" rowspan="1">1.681</td><td char="." align="char" colspan="1" rowspan="1">0.003</td><td align="left" colspan="1" rowspan="1">1.128&#8211;1.947</td></tr><tr><td align="left" colspan="1" rowspan="1">PLR (&gt;&#8201;131.28)</td><td char="." align="char" colspan="1" rowspan="1">1.565</td><td char="." align="char" colspan="1" rowspan="1">0.001</td><td align="left" colspan="1" rowspan="1">1.312&#8211;1.998</td></tr></tbody></table><table-wrap-foot><p><italic toggle="yes">ESCC</italic> esophageal squamous cell carcinoma, <italic toggle="yes">OR</italic> odds ratio, <italic toggle="yes">PLR</italic> platelet to lymphocyte ratio, <italic toggle="yes">NLR</italic> neutrophil to lymphocyte ratio, <italic toggle="yes">ERF</italic> esophageal respiratory fistula, <italic toggle="yes">CIs</italic> confidence intervals.</p></table-wrap-foot></table-wrap><table-wrap id="Tab3" position="float" orientation="portrait"><label>Table 3</label><caption><p>Multivariate logistic regression analysis of risk factors of ERF after radiotherapy for ESCC.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Parameters</th><th align="left" colspan="1" rowspan="1">OR</th><th align="left" colspan="1" rowspan="1">p value</th><th align="left" colspan="1" rowspan="1">95% CI</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1"><p>Tumor location</p><p>Neck&#8201;+&#8201;upper chest</p></td><td char="." align="char" colspan="1" rowspan="1">3.305</td><td char="." align="char" colspan="1" rowspan="1">0.039</td><td align="left" colspan="1" rowspan="1">1.064&#8211;10.266</td></tr><tr><td align="left" colspan="1" rowspan="1">T stage (T4)</td><td char="." align="char" colspan="1" rowspan="1">1.765</td><td char="." align="char" colspan="1" rowspan="1">0.002</td><td align="left" colspan="1" rowspan="1">1.057&#8211;1.815</td></tr><tr><td align="left" colspan="1" rowspan="1">Esophageal stenosis</td><td char="." align="char" colspan="1" rowspan="1">1.073</td><td char="." align="char" colspan="1" rowspan="1">0.005</td><td align="left" colspan="1" rowspan="1">1.049&#8211;1.595</td></tr><tr><td align="left" colspan="1" rowspan="1">NLR (&gt;&#8201;1.78)</td><td char="." align="char" colspan="1" rowspan="1">1.384</td><td char="." align="char" colspan="1" rowspan="1">0.005</td><td align="left" colspan="1" rowspan="1">1.137&#8211;1.515</td></tr><tr><td align="left" colspan="1" rowspan="1">PLR (&gt;&#8201;131.28)</td><td char="." align="char" colspan="1" rowspan="1">1.765</td><td char="." align="char" colspan="1" rowspan="1">0.002</td><td align="left" colspan="1" rowspan="1">1.452&#8211;1.915</td></tr></tbody></table><table-wrap-foot><p><italic toggle="yes">ESCC</italic> esophageal squamous cell carcinoma, <italic toggle="yes">OR</italic> odds ratio, <italic toggle="yes">PLR</italic> platelet to lymphocyte ratio, <italic toggle="yes">NLR</italic> neutrophil to lymphocyte ratio, <italic toggle="yes">ERF</italic> esophageal respiratory fistula, <italic toggle="yes">CIs</italic> confidence intervals.</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec14"><title>Cox proportional hazards model analyses for outcomes of ERF</title><p id="Par29">We further performed Kaplan&#8211;Meier analysis to calculate the cumulative risk of the parameters (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>). Also, neck&#8201;+&#8201;upper chest tumor location (HR 3.572, 95% CI 2.467&#8211;5.172, p&#8201;=&#8201;0.000), high T stage (HR 4.050, 95% CI 2.812&#8211;5.831, p&#8201;=&#8201;0.000), esophageal stenosis (HR 2.643, 95% CI 1.753&#8211;3.983, p&#8201;=&#8201;0.000), high PLR (HR 2.541, 95% CI 1.868&#8211;3.177, p&#8201;=&#8201;0.000) were independent prognostic factors (Table <xref rid="Tab4" ref-type="table">4</xref>).<table-wrap id="Tab4" position="float" orientation="portrait"><label>Table 4</label><caption><p>Cox proportional hazards model analyses for outcomes of ERF.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Parameters</th><th align="left" colspan="1" rowspan="1">HR</th><th align="left" colspan="1" rowspan="1">95% CI</th><th align="left" colspan="1" rowspan="1">p value</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1"><p>Tumor location</p><p>Neck&#8201;+&#8201;upper chest</p></td><td char="." align="char" colspan="1" rowspan="1">3.572</td><td align="left" colspan="1" rowspan="1">2.467&#8211;5.172</td><td char="." align="char" colspan="1" rowspan="1">0.000</td></tr><tr><td align="left" colspan="1" rowspan="1">T stage (T4)</td><td char="." align="char" colspan="1" rowspan="1">4.050</td><td align="left" colspan="1" rowspan="1">2.812&#8211;5.831</td><td char="." align="char" colspan="1" rowspan="1">0.000</td></tr><tr><td align="left" colspan="1" rowspan="1">esophageal stenosis</td><td char="." align="char" colspan="1" rowspan="1">2.643</td><td align="left" colspan="1" rowspan="1">1.753&#8211;3.983</td><td char="." align="char" colspan="1" rowspan="1">0.000</td></tr><tr><td align="left" colspan="1" rowspan="1">PLR (&gt;&#8201;131.28)</td><td char="." align="char" colspan="1" rowspan="1">2.541</td><td align="left" colspan="1" rowspan="1">1.868&#8211;3.177</td><td char="." align="char" colspan="1" rowspan="1">0.000</td></tr></tbody></table><table-wrap-foot><p><italic toggle="yes">PLR</italic> platelet to lymphocyte ratio, <italic toggle="yes">ERF</italic> esophageal respiratory fistula, <italic toggle="yes">HR</italic> hazards ratio.</p></table-wrap-foot></table-wrap></p></sec></sec><sec id="Sec15"><title>Discussion</title><p id="Par30">To our knowledge, limited studies focus on the prognostic factors of ERF associated with radiotherapy in unresectable ESCC. We found that neck&#8201;+&#8201;upper chest location, high T stage, esophageal stenosis, high NLR and PLR were risk factors for the occurrence of ERF. Cox regression analysis suggested that tumor location, high T stage, esophageal stenosis, high PLR were independent prognostic factors for poor survival. More studies have been conducted on the analysis of risk factors for ERF<sup><xref ref-type="bibr" rid="CR7">7</xref>,<xref ref-type="bibr" rid="CR17">17</xref></sup>, and EF treated with chemoradiotherapy<sup><xref ref-type="bibr" rid="CR4">4</xref></sup> and radiotherapy<sup><xref ref-type="bibr" rid="CR9">9</xref></sup>. Limited studies have focused on the prognosis factors of ERF after radiotherapy, which was a serious complication. Data indicated that the development of ERF is not only related to anatomical vulnerability resulting from contiguity between the esophagus and respiratory tract but also linked to advanced systemic illness. ERF may reduce the QoL of patients and the therapeutic effect due to serious infections<sup><xref ref-type="bibr" rid="CR18">18</xref></sup>. On the contrary, a case&#8211;control study conducted for patients with ESCC and ERF matching a period of 10&#160;years showed that there is no correlation between any therapeutic strategy and ERF formation<sup><xref ref-type="bibr" rid="CR7">7</xref></sup>. In the present study, we not only demonstrated the risk factors of tracheal fistula after radiotherapy for ESCC. More importantly, we found the prognostic factors and highlighted the higher risk of death or severe adverse events in patients with ERF compared to controls in the 2-year follow-up.</p><p id="Par31">The stent placement is considered as the primary treatment strategy for patients with ERF. In our study, 25% of ERF patients received stent because of airway stenosis due to esophageal cancer invasion and external pressure. However, metal stent implantation itself can be a risk factor leading to ERF formation due to compression and necrosis of the esophagus wall<sup><xref ref-type="bibr" rid="CR19">19</xref></sup>. The development of ERF was observed to be up to 9.4-fold higher in patients who underwent prior radiation therapy after esophageal stent placement<sup><xref ref-type="bibr" rid="CR20">20</xref>,<xref ref-type="bibr" rid="CR21">21</xref></sup>. Particularly, another study found no correlation between radiotherapy and ERF formation. The type of stent and patient&#8217;s disease status may be responsible for the controversy.</p><p id="Par32">Regarding the risk factors of fistula formation, a study revealed that patients with T4 stage in EC were more likely to develop ERF after CRT, with an incidence of 18&#8211;29%. The number of patients with ERF in stage T4 was 1.42 times higher than controls<sup><xref ref-type="bibr" rid="CR9">9</xref></sup>. Another study also suggested that high tumor stage leads to ERF formation after radiotherapy<sup><xref ref-type="bibr" rid="CR2">2</xref></sup>. In agreement with Sivaraman<sup><xref ref-type="bibr" rid="CR22">22</xref></sup>, we highlighted that the prognostic value of high T4 stage in ERF was clinically important, indicating that the tumor can extensively invade adjacent tissues including the airway wall in patients with high T-stage.</p><p id="Par33">Because of different definitions of esophageal stenosis and small sample sizes, there were inconsistent results on the relationship between esophageal stenosis and esophageal fistula in patients with locally advanced ESCC who receive radiotherapy<sup><xref ref-type="bibr" rid="CR4">4</xref>,<xref ref-type="bibr" rid="CR23">23</xref></sup>. Yang reported that esophageal luminal stenosis has a significant impact on the OS in patients with resected ESCC, and it may provide additional prognostic value to the current staging system before any cancer-specific treatment<sup><xref ref-type="bibr" rid="CR12">12</xref></sup>, which supporting our findings. Mariette et al. determined the prognostic significance of failure to cross esophageal tumors by endoluminal ultrasound. They observed the median 5-year survival in patients whose tumors were not crossed was shorter compared with controls<sup><xref ref-type="bibr" rid="CR24">24</xref></sup>. EF was more likely to occur when the esophageal diameter was&#8201;&lt;&#8201;0.5&#160;cm<sup><xref ref-type="bibr" rid="CR9">9</xref></sup>. The exact mechanism of how esophageal stenosis leads to the development of ERF is not fully understood. We hypothesized that the factors include inadequate control of the primary tumor, the friction of food on the esophagus, continued growth of the remaining tumor bed after radiotherapy, and fibrosis contraction of the esophageal tumor tissue.</p><p id="Par34">There were also some disagreements among studies regarding the effect of tumor location on the prognosis of EF<sup><xref ref-type="bibr" rid="CR9">9</xref>,<xref ref-type="bibr" rid="CR20">20</xref>,<xref ref-type="bibr" rid="CR25">25</xref></sup>. We were supported by Bick that the region between 20 and 25&#160;cm from the incisors is a &#8220;hot spot&#8221; for fistula formation<sup><xref ref-type="bibr" rid="CR20">20</xref></sup>. Indeed, Kassis et al. found that tumors located in the neck&#8201;+&#8201;upper thoracic segment were associated with a higher incidence of ERF<sup><xref ref-type="bibr" rid="CR25">25</xref></sup>. The distance of the pars membranacea of the trachea to the esophagus is often less than 0.5&#160;mm for a distance of 7&#8211;8&#160;cm in the posterior mediastinum<sup><xref ref-type="bibr" rid="CR26">26</xref></sup>. This might be explained by the anatomical proximity of the trachea to the esophagus in this region.</p><p id="Par35">Growing evidence has suggested that the tumor progression and prognosis are associated with features of tumor and host inflammation response<sup><xref ref-type="bibr" rid="CR27">27</xref></sup>. A systemic inflammatory response has a vital role in cell proliferation, invasion and migration as well as the response to treatment<sup><xref ref-type="bibr" rid="CR28">28</xref></sup>. Elevated level of pretreatment inflammatory indicators were significantly related with prognosis for ESCC patients who underwent curative esophagectomy or definitive chemoradiotherapy<sup><xref ref-type="bibr" rid="CR29">29</xref></sup>. To our knowledge, high neutrophil to lymphocyte ratio (NLR) and platelet to lymphocyte ratio (PLR) have been reported to be associated with poor overall survival (OS) and malignant phenotypes such as deeper depth of invasion, positive lymph node metastasis and advanced TNM stage<sup><xref ref-type="bibr" rid="CR30">30</xref></sup>. We thought that pretreatment NLR and PLR can be easily measured and are inexpensive tests. It confirmed that pretreatment NLR is an independent factor to predict grade&#8201;&#8805;&#8201;3 hematologic toxicity in ESCC patients treated with CRT, which was in favor with our report. It provides an effective way for clinicians to identify high-risk ESCC patients with worse prognosis or severe adverse events before treatment and timely adjust individualized treatment or perform pretreatment measures<sup><xref ref-type="bibr" rid="CR31">31</xref></sup>. Besides, the role of systemic inflammation in the development of ERF has yet to be defined. We were supported by previous study to some extent which revealed that esophageal stenosis, ulcerative tumor, and PLR were independent factors for EF in ESCC patients who received radiotherapy. These findings will help to facilitate individual risk stratification for the development of EF in patients with ESCC<sup><xref ref-type="bibr" rid="CR32">32</xref></sup>. The detailed mechanism about inflammatory on tumor and ERF is still unclear. Neutrophils could promote tumor cell proliferation by producing proteolytic enzymes and serine proteases, and stimulate tumor angiogenesis by releasing proangiogenic factor<sup><xref ref-type="bibr" rid="CR33">33</xref></sup>. Platelets could stabilize tumor cell arrest in the vasculature, stimulate tumor cell proliferation and promote tumor cells extravasation<sup><xref ref-type="bibr" rid="CR34">34</xref></sup>. Our study provided the first evidence that both high NLR and PLR are independent prognostic markers of ERF in ESCC patients after radiotherapy, including death or severe adverse events. Notably, the indicators are collected when ERF is diagnosed, and the value of PLR and NLR at different time worth exploring.</p><p id="Par36">It&#8217;s worth noting that the conventional segmented dose of radiotherapy for ESCC is typically 1.8&#8211;2.0&#160;Gy. The association between fraction dose of radiotherapy and ERF remains unclear<sup><xref ref-type="bibr" rid="CR10">10</xref></sup>. It has been suggested that high doses (&gt;&#8201;2.0&#160;Gy) may lead to a risk for ERF development. And the hazard ratio for death revealed no significant difference in OS rates between high-dose and low-dose radiotherapy groups in eligible patients with ERF<sup><xref ref-type="bibr" rid="CR35">35</xref></sup>. We also failed to find any difference in the rate of ERF among different doses of radiotherapy, which was in consistent with Tsushima's findings<sup><xref ref-type="bibr" rid="CR32">32</xref></sup>.</p><p id="Par37">This study has several limitations. Firstly, the sample size was relatively small, which may limit the generalizability of the findings. The incidence rate of ERF from our finding was relatively higher compared with previous studies<sup><xref ref-type="bibr" rid="CR4">4</xref>,<xref ref-type="bibr" rid="CR36">36</xref>,<xref ref-type="bibr" rid="CR37">37</xref></sup>. It should be noted that we focus on the long follow-up after radiotherapy. And the heterogeneity of patients should be mentioned based on the significant difference in sequential radiotherapy&#8201;+&#8201;chemotherapy between groups. Secondly, although most parameters investigated were objective, esophageal stenosis assessed by the endoscopy was not performed by the same specialist. Therefore, inter-observer bias may exist. Thirdly, due to the design of single-center, caution should be taken when generalizing the conclusions. Fourthly, it was difficult to determine whether ERF was caused by radiotherapy or disease progression to some extent.</p></sec><sec id="Sec16"><title>Conclusion</title><p id="Par38">In summary, esophageal stenosis, neck&#8201;+&#8201;upper chest tumor location, high T stage and PLR could predict the prognosis of ERF in ESCC patients who underwent radiotherapy. We ought to attach importance to the prevention and individualized treatment of ERF.</p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>ESCC</term><def><p id="Par2">Esophageal squamous cell carcinoma</p></def></def-item><def-item><term>ERF</term><def><p id="Par3">Esophageal respiratory fistula</p></def></def-item><def-item><term>EF</term><def><p id="Par4">Esophageal fistula</p></def></def-item><def-item><term>OR</term><def><p id="Par5">Odds ratio</p></def></def-item><def-item><term>HR</term><def><p id="Par6">Hazards ratio</p></def></def-item><def-item><term>CIs</term><def><p id="Par7">Confidence intervals</p></def></def-item><def-item><term>PLR</term><def><p id="Par8">Platelet to lymphocyte ratio</p></def></def-item><def-item><term>NLR</term><def><p id="Par9">Neutrophil to lymphocyte ratio</p></def></def-item><def-item><term>QoL</term><def><p id="Par10">Quality of life</p></def></def-item><def-item><term>OS</term><def><p id="Par11">Overall survival</p></def></def-item><def-item><term>BMI</term><def><p id="Par12">Body mass index</p></def></def-item><def-item><term>KPS</term><def><p id="Par13">Karnofsky performance status</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Publisher's note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn><fn><p>These authors contributed equally: Jia-Chao Qi and Lijia Zhi.</p></fn></fn-group><ack><title>Acknowledgements</title><p>The authors are grateful to the staffs of Department of Intensive Critical Care Unit and Department of Department of Respiratory and Critical Care Medicine in the collection and analysis of data.</p></ack><notes notes-type="author-contribution"><title>Author contributions</title><p>Jiachao Qi and Lijia Zhi conceived the study. Jia-Chao Qi, Lijia Zhi and Hao Li designed and analyzed the data and contributed to the manuscript preparation. Yanping Huang, Tie-Zhu Wang, Li Lin and Huangyu Li contributed to the design of the study and analyzed the data. Yu-Ming Ye contributed to the revision of the manuscript. All authors read and approved the final manuscript. Jiachao Qi and Lijia Zhi contributed equally to this manuscript. The authors affirm that human research participants provided informed consent for publication.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>This work was funded by grants PDA202203 for Grade A for scientific research of Zhangzhou Affiliated Hospital of Fujian Medical University, Grant 2023J01122413 Natural Science Foundation of Fujian Province, Grant ZZ2023J19 Natural Science Foundation of Zhangzhou.</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.</p></notes><notes id="FPar1" notes-type="COI-statement"><title>Competing interests</title><p id="Par39">The authors declare no competing interests.</p></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rogers</surname><given-names>JE</given-names></name><name name-style="western"><surname>Sewastjanow-Silva</surname><given-names>M</given-names></name><name name-style="western"><surname>Waters</surname><given-names>RE</given-names></name><name name-style="western"><surname>Ajani</surname><given-names>JA</given-names></name></person-group><article-title>Esophageal cancer: Emerging therapeutics</article-title><source>Expert Opin. Therap. Targets</source><year>2022</year><volume>26</volume><issue>2</issue><fpage>107</fpage><lpage>117</lpage><pub-id pub-id-type="doi">10.1080/14728222.2022.2036718</pub-id><pub-id pub-id-type="pmid">35119973</pub-id></element-citation><mixed-citation id="mc-CR1" publication-type="journal">Rogers, J. E., Sewastjanow-Silva, M., Waters, R. E. &amp; Ajani, J. A. Esophageal cancer: Emerging therapeutics. <italic toggle="yes">Expert Opin. Therap. Targets</italic><bold>26</bold>(2), 107&#8211;117 (2022).<pub-id pub-id-type="pmid">35119973</pub-id><pub-id pub-id-type="doi">10.1080/14728222.2022.2036718</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pao</surname><given-names>TH</given-names></name><name name-style="western"><surname>Chang</surname><given-names>WL</given-names></name><name name-style="western"><surname>Chiang</surname><given-names>NJ</given-names></name><name name-style="western"><surname>Chang</surname><given-names>JS</given-names></name><name name-style="western"><surname>Lin</surname><given-names>CY</given-names></name><name name-style="western"><surname>Lai</surname><given-names>WW</given-names></name><name name-style="western"><surname>Tseng</surname><given-names>YL</given-names></name><name name-style="western"><surname>Yen</surname><given-names>YT</given-names></name><name name-style="western"><surname>Chung</surname><given-names>TJ</given-names></name><name name-style="western"><surname>Lin</surname><given-names>FC</given-names></name></person-group><article-title>Cardiac radiation dose predicts survival in esophageal squamous cell carcinoma treated by definitive concurrent chemotherapy and intensity modulated radiotherapy</article-title><source>Radiat. Oncol.</source><year>2020</year><volume>15</volume><issue>1</issue><fpage>221</fpage><pub-id pub-id-type="doi">10.1186/s13014-020-01664-7</pub-id><pub-id pub-id-type="pmid">32962730</pub-id><pub-id pub-id-type="pmcid">PMC7510071</pub-id></element-citation><mixed-citation id="mc-CR2" publication-type="journal">Pao, T. H. <italic toggle="yes">et al.</italic> Cardiac radiation dose predicts survival in esophageal squamous cell carcinoma treated by definitive concurrent chemotherapy and intensity modulated radiotherapy. <italic toggle="yes">Radiat. Oncol.</italic><bold>15</bold>(1), 221 (2020).<pub-id pub-id-type="pmid">32962730</pub-id><pub-id pub-id-type="doi">10.1186/s13014-020-01664-7</pub-id><pub-id pub-id-type="pmcid">PMC7510071</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shinoda</surname><given-names>M</given-names></name><name name-style="western"><surname>Ando</surname><given-names>N</given-names></name><name name-style="western"><surname>Kato</surname><given-names>K</given-names></name><name name-style="western"><surname>Ishikura</surname><given-names>S</given-names></name><name name-style="western"><surname>Kato</surname><given-names>H</given-names></name><name name-style="western"><surname>Tsubosa</surname><given-names>Y</given-names></name><name name-style="western"><surname>Minashi</surname><given-names>K</given-names></name><name name-style="western"><surname>Okabe</surname><given-names>H</given-names></name><name name-style="western"><surname>Kimura</surname><given-names>Y</given-names></name><name name-style="western"><surname>Kawano</surname><given-names>T</given-names></name><etal/></person-group><article-title>Randomized study of low-dose versus standard-dose chemoradiotherapy for unresectable esophageal squamous cell carcinoma (JCOG0303)</article-title><source>Cancer Sci.</source><year>2015</year><volume>106</volume><issue>4</issue><fpage>407</fpage><lpage>412</lpage><pub-id pub-id-type="doi">10.1111/cas.12622</pub-id><pub-id pub-id-type="pmid">25640628</pub-id><pub-id pub-id-type="pmcid">PMC4409884</pub-id></element-citation><mixed-citation id="mc-CR3" publication-type="journal">Shinoda, M. <italic toggle="yes">et al.</italic> Randomized study of low-dose versus standard-dose chemoradiotherapy for unresectable esophageal squamous cell carcinoma (JCOG0303). <italic toggle="yes">Cancer Sci.</italic><bold>106</bold>(4), 407&#8211;412 (2015).<pub-id pub-id-type="pmid">25640628</pub-id><pub-id pub-id-type="doi">10.1111/cas.12622</pub-id><pub-id pub-id-type="pmcid">PMC4409884</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Takeshi</surname><given-names>K</given-names></name><name name-style="western"><surname>Takahiro</surname><given-names>T</given-names></name><name name-style="western"><surname>Katsuhiro</surname><given-names>O</given-names></name><name name-style="western"><surname>Hirofumi</surname><given-names>O</given-names></name><name name-style="western"><surname>Hiromichi</surname><given-names>S</given-names></name><name name-style="western"><surname>Yosuke</surname><given-names>K</given-names></name><name name-style="western"><surname>Yukio</surname><given-names>Y</given-names></name><name name-style="western"><surname>Satoshi</surname><given-names>H</given-names></name><name name-style="western"><surname>Akiko</surname><given-names>T</given-names></name><name name-style="western"><surname>Nozomu</surname><given-names>M</given-names></name></person-group><article-title>Risk factors for esophageal fistula in thoracic esophageal squamous cell carcinoma invading adjacent organs treated with definitive chemoradiotherapy: A monocentric case-control study</article-title><source>BMC Cancer</source><year>2018</year><volume>18</volume><issue>1</issue><fpage>573</fpage><pub-id pub-id-type="doi">10.1186/s12885-018-4486-3</pub-id><pub-id pub-id-type="pmid">29776344</pub-id><pub-id pub-id-type="pmcid">PMC5960135</pub-id></element-citation><mixed-citation id="mc-CR4" publication-type="journal">Takeshi, K. <italic toggle="yes">et al.</italic> Risk factors for esophageal fistula in thoracic esophageal squamous cell carcinoma invading adjacent organs treated with definitive chemoradiotherapy: A monocentric case-control study. <italic toggle="yes">BMC Cancer</italic><bold>18</bold>(1), 573 (2018).<pub-id pub-id-type="pmid">29776344</pub-id><pub-id pub-id-type="doi">10.1186/s12885-018-4486-3</pub-id><pub-id pub-id-type="pmcid">PMC5960135</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hihara</surname><given-names>J</given-names></name><name name-style="western"><surname>Hamai</surname><given-names>Y</given-names></name><name name-style="western"><surname>Emi</surname><given-names>M</given-names></name><name name-style="western"><surname>Aoki</surname><given-names>Y</given-names></name><name name-style="western"><surname>Taomoto</surname><given-names>J</given-names></name><name name-style="western"><surname>Miyata</surname><given-names>Y</given-names></name><name name-style="western"><surname>Okada</surname><given-names>M</given-names></name></person-group><article-title>Esophageal bypass operation prior to definitive chemoradiotherapy in advanced esophageal cancer with tracheobronchial invasion</article-title><source>Ann. Thorac. Surg.</source><year>2014</year><volume>97</volume><issue>1</issue><fpage>290</fpage><lpage>295</lpage><pub-id pub-id-type="doi">10.1016/j.athoracsur.2013.08.060</pub-id><pub-id pub-id-type="pmid">24200399</pub-id></element-citation><mixed-citation id="mc-CR5" publication-type="journal">Hihara, J. <italic toggle="yes">et al.</italic> Esophageal bypass operation prior to definitive chemoradiotherapy in advanced esophageal cancer with tracheobronchial invasion. <italic toggle="yes">Ann. Thorac. Surg.</italic><bold>97</bold>(1), 290&#8211;295 (2014).<pub-id pub-id-type="pmid">24200399</pub-id><pub-id pub-id-type="doi">10.1016/j.athoracsur.2013.08.060</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kinsman</surname><given-names>KJ</given-names></name><name name-style="western"><surname>DeGregorio</surname><given-names>BT</given-names></name><name name-style="western"><surname>Katon</surname><given-names>RM</given-names></name><name name-style="western"><surname>Morrison</surname><given-names>K</given-names></name><name name-style="western"><surname>Saxon</surname><given-names>RR</given-names></name><name name-style="western"><surname>Keller</surname><given-names>FS</given-names></name><name name-style="western"><surname>Rosch</surname><given-names>J</given-names></name></person-group><article-title>Prior radiation and chemotherapy increase the risk of life-threatening complications after insertion of metallic stents for esophagogastric malignancy</article-title><source>Gastrointest. Endosc.</source><year>1996</year><volume>43</volume><issue>3</issue><fpage>196</fpage><lpage>203</lpage><pub-id pub-id-type="doi">10.1016/S0016-5107(96)70315-2</pub-id><pub-id pub-id-type="pmid">8857133</pub-id></element-citation><mixed-citation id="mc-CR6" publication-type="journal">Kinsman, K. J. <italic toggle="yes">et al.</italic> Prior radiation and chemotherapy increase the risk of life-threatening complications after insertion of metallic stents for esophagogastric malignancy. <italic toggle="yes">Gastrointest. Endosc.</italic><bold>43</bold>(3), 196&#8211;203 (1996).<pub-id pub-id-type="pmid">8857133</pub-id><pub-id pub-id-type="doi">10.1016/S0016-5107(96)70315-2</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Paul</surname><given-names>G</given-names></name><name name-style="western"><surname>Bohle</surname><given-names>W</given-names></name><name name-style="western"><surname>Zoller</surname><given-names>W</given-names></name></person-group><article-title>Risk factors for the development of esophagorespiratory fistula in esophageal cancer</article-title><source>J. Gastrointest. Liver Dis.</source><year>2019</year><volume>28</volume><issue>3</issue><fpage>265</fpage><lpage>270</lpage><pub-id pub-id-type="doi">10.15403/jgld-271</pub-id><pub-id pub-id-type="pmid">31517322</pub-id></element-citation><mixed-citation id="mc-CR7" publication-type="journal">Paul, G., Bohle, W. &amp; Zoller, W. Risk factors for the development of esophagorespiratory fistula in esophageal cancer. <italic toggle="yes">J. Gastrointest. Liver Dis.</italic><bold>28</bold>(3), 265&#8211;270 (2019).<pub-id pub-id-type="doi">10.15403/jgld-271</pub-id><pub-id pub-id-type="pmid">31517322</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Satija</surname><given-names>L</given-names></name><name name-style="western"><surname>Joshi</surname><given-names>P</given-names></name><name name-style="western"><surname>George</surname><given-names>R</given-names></name><name name-style="western"><surname>Singh</surname><given-names>S</given-names></name></person-group><article-title>An unusual case of malignant oesophago-pulmonary fistula diagnosed by multidetector computed tomography</article-title><source>Med. J. Armed Forces India</source><year>2012</year><volume>68</volume><issue>1</issue><fpage>72</fpage><lpage>74</lpage><pub-id pub-id-type="doi">10.1016/S0377-1237(11)60108-1</pub-id><pub-id pub-id-type="pmid">24623921</pub-id><pub-id pub-id-type="pmcid">PMC3862967</pub-id></element-citation><mixed-citation id="mc-CR8" publication-type="journal">Satija, L., Joshi, P., George, R. &amp; Singh, S. An unusual case of malignant oesophago-pulmonary fistula diagnosed by multidetector computed tomography. <italic toggle="yes">Med. J. Armed Forces India</italic><bold>68</bold>(1), 72&#8211;74 (2012).<pub-id pub-id-type="pmid">24623921</pub-id><pub-id pub-id-type="doi">10.1016/S0377-1237(11)60108-1</pub-id><pub-id pub-id-type="pmcid">PMC3862967</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hu</surname><given-names>B</given-names></name><name name-style="western"><surname>Jia</surname><given-names>F</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>H</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>T</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Q</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y</given-names></name><name name-style="western"><surname>Li</surname><given-names>B</given-names></name><name name-style="western"><surname>Huang</surname><given-names>W</given-names></name></person-group><article-title>Risk factors associated with esophageal fistula after radiotherapy for esophageal squamous cell carcinoma</article-title><source>J. Cancer</source><year>2020</year><volume>11</volume><issue>12</issue><fpage>3693</fpage><lpage>3700</lpage><pub-id pub-id-type="doi">10.7150/jca.39033</pub-id><pub-id pub-id-type="pmid">32284766</pub-id><pub-id pub-id-type="pmcid">PMC7150448</pub-id></element-citation><mixed-citation id="mc-CR9" publication-type="journal">Hu, B. <italic toggle="yes">et al.</italic> Risk factors associated with esophageal fistula after radiotherapy for esophageal squamous cell carcinoma. <italic toggle="yes">J. Cancer</italic><bold>11</bold>(12), 3693&#8211;3700 (2020).<pub-id pub-id-type="pmid">32284766</pub-id><pub-id pub-id-type="doi">10.7150/jca.39033</pub-id><pub-id pub-id-type="pmcid">PMC7150448</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Li</surname><given-names>Z</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>W</given-names></name><name name-style="western"><surname>Chen</surname><given-names>W</given-names></name><name name-style="western"><surname>Song</surname><given-names>Y</given-names></name></person-group><article-title>Risk factors for esophageal fistula in patients with locally advanced esophageal carcinoma receiving chemoradiotherapy</article-title><source>OncoTargets Ther.</source><year>2018</year><volume>11</volume><fpage>2311</fpage><lpage>2317</lpage><pub-id pub-id-type="doi">10.2147/OTT.S161803</pub-id><pub-id pub-id-type="pmcid">PMC5923220</pub-id><pub-id pub-id-type="pmid">29731639</pub-id></element-citation><mixed-citation id="mc-CR10" publication-type="journal">Zhang, Y., Li, Z., Zhang, W., Chen, W. &amp; Song, Y. Risk factors for esophageal fistula in patients with locally advanced esophageal carcinoma receiving chemoradiotherapy. <italic toggle="yes">OncoTargets Ther.</italic><bold>11</bold>, 2311&#8211;2317 (2018).<pub-id pub-id-type="doi">10.2147/OTT.S161803</pub-id><pub-id pub-id-type="pmcid">PMC5923220</pub-id><pub-id pub-id-type="pmid">29731639</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Suresh</surname><given-names>R</given-names></name><name name-style="western"><surname>Yu</surname><given-names>HJ</given-names></name><name name-style="western"><surname>Thoveson</surname><given-names>A</given-names></name><name name-style="western"><surname>Swisher</surname><given-names>J</given-names></name><name name-style="western"><surname>Apolinario</surname><given-names>M</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>B</given-names></name><name name-style="western"><surname>Shah</surname><given-names>AR</given-names></name><name name-style="western"><surname>Fish</surname><given-names>RH</given-names></name><name name-style="western"><surname>Wykoff</surname><given-names>CC</given-names></name></person-group><article-title>Loss to follow-up among patients with proliferative diabetic retinopathy in clinical practice</article-title><source>Am. J. Ophthalmol.</source><year>2020</year><volume>215</volume><fpage>66</fpage><lpage>71</lpage><pub-id pub-id-type="doi">10.1016/j.ajo.2020.03.011</pub-id><pub-id pub-id-type="pmid">32209344</pub-id></element-citation><mixed-citation id="mc-CR11" publication-type="journal">Suresh, R. <italic toggle="yes">et al.</italic> Loss to follow-up among patients with proliferative diabetic retinopathy in clinical practice. <italic toggle="yes">Am. J. Ophthalmol.</italic><bold>215</bold>, 66&#8211;71 (2020).<pub-id pub-id-type="pmid">32209344</pub-id><pub-id pub-id-type="doi">10.1016/j.ajo.2020.03.011</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>YS</given-names></name><name name-style="western"><surname>Hu</surname><given-names>WP</given-names></name><name name-style="western"><surname>Ni</surname><given-names>PZ</given-names></name><name name-style="western"><surname>Wang</surname><given-names>WP</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>Y</given-names></name><name name-style="western"><surname>Chen</surname><given-names>LQ</given-names></name></person-group><article-title>Esophageal luminal stenosis is an independent prognostic factor in esophageal squamous cell carcinoma</article-title><source>Oncotarget</source><year>2017</year><volume>8</volume><issue>26</issue><fpage>43397</fpage><lpage>43405</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.14762</pub-id><pub-id pub-id-type="pmid">28118615</pub-id><pub-id pub-id-type="pmcid">PMC5522155</pub-id></element-citation><mixed-citation id="mc-CR12" publication-type="journal">Yang, Y. S. <italic toggle="yes">et al.</italic> Esophageal luminal stenosis is an independent prognostic factor in esophageal squamous cell carcinoma. <italic toggle="yes">Oncotarget</italic><bold>8</bold>(26), 43397&#8211;43405 (2017).<pub-id pub-id-type="pmid">28118615</pub-id><pub-id pub-id-type="doi">10.18632/oncotarget.14762</pub-id><pub-id pub-id-type="pmcid">PMC5522155</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>W</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Sun</surname><given-names>J</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>T</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>B</given-names></name><name name-style="western"><surname>Li</surname><given-names>B</given-names></name></person-group><article-title>Atlas of the thoracic lymph nodal delineation and recommendations for lymph nodal CTV of esophageal squamous cell cancer in radiation therapy from China</article-title><source>Radiother. Oncol.</source><year>2015</year><volume>116</volume><issue>1</issue><fpage>100</fpage><lpage>106</lpage><pub-id pub-id-type="doi">10.1016/j.radonc.2015.06.024</pub-id><pub-id pub-id-type="pmid">26142269</pub-id></element-citation><mixed-citation id="mc-CR13" publication-type="journal">Huang, W. <italic toggle="yes">et al.</italic> Atlas of the thoracic lymph nodal delineation and recommendations for lymph nodal CTV of esophageal squamous cell cancer in radiation therapy from China. <italic toggle="yes">Radiother. Oncol.</italic><bold>116</bold>(1), 100&#8211;106 (2015).<pub-id pub-id-type="pmid">26142269</pub-id><pub-id pub-id-type="doi">10.1016/j.radonc.2015.06.024</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yamada</surname><given-names>K</given-names></name><name name-style="western"><surname>Murakami</surname><given-names>M</given-names></name><name name-style="western"><surname>Okamoto</surname><given-names>Y</given-names></name><name name-style="western"><surname>Okuno</surname><given-names>Y</given-names></name><name name-style="western"><surname>Nakajima</surname><given-names>T</given-names></name><name name-style="western"><surname>Kusumi</surname><given-names>F</given-names></name><name name-style="western"><surname>Takakuwa</surname><given-names>H</given-names></name><name name-style="western"><surname>Matsusue</surname><given-names>S</given-names></name></person-group><article-title>Treatment results of chemoradiotherapy for clinical stage I (T1N0M0) esophageal carcinoma</article-title><source>Int. J. Radiat. Oncol. Biol. Phys.</source><year>2006</year><volume>64</volume><issue>4</issue><fpage>1106</fpage><lpage>1111</lpage><pub-id pub-id-type="doi">10.1016/j.ijrobp.2005.10.015</pub-id><pub-id pub-id-type="pmid">16504758</pub-id></element-citation><mixed-citation id="mc-CR14" publication-type="journal">Yamada, K. <italic toggle="yes">et al.</italic> Treatment results of chemoradiotherapy for clinical stage I (T1N0M0) esophageal carcinoma. <italic toggle="yes">Int. J. Radiat. Oncol. Biol. Phys.</italic><bold>64</bold>(4), 1106&#8211;1111 (2006).<pub-id pub-id-type="pmid">16504758</pub-id><pub-id pub-id-type="doi">10.1016/j.ijrobp.2005.10.015</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Metlay</surname><given-names>JP</given-names></name><name name-style="western"><surname>Waterer</surname><given-names>GW</given-names></name><name name-style="western"><surname>Long</surname><given-names>AC</given-names></name><name name-style="western"><surname>Anzueto</surname><given-names>A</given-names></name><name name-style="western"><surname>Brozek</surname><given-names>J</given-names></name><name name-style="western"><surname>Crothers</surname><given-names>K</given-names></name><name name-style="western"><surname>Cooley</surname><given-names>LA</given-names></name><name name-style="western"><surname>Dean</surname><given-names>NC</given-names></name><name name-style="western"><surname>Fine</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Flanders</surname><given-names>SA</given-names></name><etal/></person-group><article-title>Diagnosis and treatment of adults with community-acquired pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America</article-title><source>Am. J. Respir. Crit. Care Med.</source><year>2019</year><volume>200</volume><issue>7</issue><fpage>e45</fpage><lpage>e67</lpage><pub-id pub-id-type="doi">10.1164/rccm.201908-1581ST</pub-id><pub-id pub-id-type="pmid">31573350</pub-id><pub-id pub-id-type="pmcid">PMC6812437</pub-id></element-citation><mixed-citation id="mc-CR15" publication-type="journal">Metlay, J. P. <italic toggle="yes">et al.</italic> Diagnosis and treatment of adults with community-acquired pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America. <italic toggle="yes">Am. J. Respir. Crit. Care Med.</italic><bold>200</bold>(7), e45&#8211;e67 (2019).<pub-id pub-id-type="pmid">31573350</pub-id><pub-id pub-id-type="doi">10.1164/rccm.201908-1581ST</pub-id><pub-id pub-id-type="pmcid">PMC6812437</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jin</surname><given-names>F</given-names></name><name name-style="western"><surname>Li</surname><given-names>Q</given-names></name><name name-style="western"><surname>Bai</surname><given-names>C</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H</given-names></name><name name-style="western"><surname>Li</surname><given-names>S</given-names></name><name name-style="western"><surname>Song</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zeng</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>R</given-names></name><name name-style="western"><surname>Li</surname><given-names>W</given-names></name><name name-style="western"><surname>Hu</surname><given-names>C</given-names></name><etal/></person-group><article-title>Chinese expert recommendation for diagnosis and treatment of massive hemoptysis</article-title><source>Respir. Int. Rev. Thorac. Dis.</source><year>2020</year><volume>99</volume><issue>1</issue><fpage>83</fpage><lpage>92</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1159/000502156</pub-id><pub-id pub-id-type="pmid">31509823</pub-id></element-citation><mixed-citation id="mc-CR16" publication-type="journal">Jin, F. <italic toggle="yes">et al.</italic> Chinese expert recommendation for diagnosis and treatment of massive hemoptysis. <italic toggle="yes">Respir. Int. Rev. Thorac. Dis.</italic><bold>99</bold>(1), 83&#8211;92 (2020).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1159/000502156</pub-id><pub-id pub-id-type="pmid">31509823</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ohsawa</surname><given-names>M</given-names></name><name name-style="western"><surname>Hamai</surname><given-names>Y</given-names></name><name name-style="western"><surname>Ibuki</surname><given-names>Y</given-names></name><name name-style="western"><surname>Emi</surname><given-names>M</given-names></name><name name-style="western"><surname>Miyata</surname><given-names>Y</given-names></name><name name-style="western"><surname>Okada</surname><given-names>M</given-names></name></person-group><article-title>Long-term esophageal cancer survivor treated by bypass for esophagobronchial fistula after chemoradiotherapy: A case report</article-title><source>Anticancer Res.</source><year>2019</year><volume>39</volume><issue>8</issue><fpage>4399</fpage><lpage>4403</lpage><pub-id pub-id-type="doi">10.21873/anticanres.13610</pub-id><pub-id pub-id-type="pmid">31366536</pub-id></element-citation><mixed-citation id="mc-CR17" publication-type="journal">Ohsawa, M. <italic toggle="yes">et al.</italic> Long-term esophageal cancer survivor treated by bypass for esophagobronchial fistula after chemoradiotherapy: A case report. <italic toggle="yes">Anticancer Res.</italic><bold>39</bold>(8), 4399&#8211;4403 (2019).<pub-id pub-id-type="pmid">31366536</pub-id><pub-id pub-id-type="doi">10.21873/anticanres.13610</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ohtsu</surname><given-names>A</given-names></name><name name-style="western"><surname>Boku</surname><given-names>N</given-names></name><name name-style="western"><surname>Muro</surname><given-names>K</given-names></name><name name-style="western"><surname>Chin</surname><given-names>K</given-names></name><name name-style="western"><surname>Muto</surname><given-names>M</given-names></name><name name-style="western"><surname>Yoshida</surname><given-names>S</given-names></name><name name-style="western"><surname>Satake</surname><given-names>M</given-names></name><name name-style="western"><surname>Ishikura</surname><given-names>S</given-names></name><name name-style="western"><surname>Ogino</surname><given-names>T</given-names></name><name name-style="western"><surname>Miyata</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Definitive chemoradiotherapy for T4 and/or M1 lymph node squamous cell carcinoma of the esophagus</article-title><source>J. Clin. Oncol.</source><year>1999</year><volume>17</volume><issue>9</issue><fpage>2915</fpage><lpage>2921</lpage><pub-id pub-id-type="doi">10.1200/JCO.1999.17.9.2915</pub-id><pub-id pub-id-type="pmid">10561371</pub-id></element-citation><mixed-citation id="mc-CR18" publication-type="journal">Ohtsu, A. <italic toggle="yes">et al.</italic> Definitive chemoradiotherapy for T4 and/or M1 lymph node squamous cell carcinoma of the esophagus. <italic toggle="yes">J. Clin. Oncol.</italic><bold>17</bold>(9), 2915&#8211;2921 (1999).<pub-id pub-id-type="pmid">10561371</pub-id><pub-id pub-id-type="doi">10.1200/JCO.1999.17.9.2915</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ke</surname><given-names>M</given-names></name><name name-style="western"><surname>Wu</surname><given-names>X</given-names></name><name name-style="western"><surname>Zeng</surname><given-names>J</given-names></name></person-group><article-title>The treatment strategy for tracheoesophageal fistula</article-title><source>J. Thorac. Dis.</source><year>2015</year><volume>7</volume><issue>Suppl 4</issue><fpage>S389</fpage><lpage>S397</lpage><pub-id pub-id-type="pmid">26807286</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3978/j.issn.2072-1439.2015.12.11</pub-id><pub-id pub-id-type="pmcid">PMC4700364</pub-id></element-citation><mixed-citation id="mc-CR19" publication-type="journal">Ke, M., Wu, X. &amp; Zeng, J. The treatment strategy for tracheoesophageal fistula. <italic toggle="yes">J. Thorac. Dis.</italic><bold>7</bold>(Suppl 4), S389&#8211;S397 (2015).<pub-id pub-id-type="pmid">26807286</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3978/j.issn.2072-1439.2015.12.11</pub-id><pub-id pub-id-type="pmcid">PMC4700364</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bick</surname><given-names>BL</given-names></name><name name-style="western"><surname>Song</surname><given-names>LM</given-names></name><name name-style="western"><surname>Buttar</surname><given-names>NS</given-names></name><name name-style="western"><surname>Baron</surname><given-names>TH</given-names></name><name name-style="western"><surname>Nichols</surname><given-names>FC</given-names></name><name name-style="western"><surname>Maldonado</surname><given-names>F</given-names></name><name name-style="western"><surname>Katzka</surname><given-names>DA</given-names></name><name name-style="western"><surname>Enders</surname><given-names>FT</given-names></name><name name-style="western"><surname>Topazian</surname><given-names>MD</given-names></name></person-group><article-title>Stent-associated esophagorespiratory fistulas: Incidence and risk factors</article-title><source>Gastrointest. Endosc.</source><year>2013</year><volume>77</volume><issue>2</issue><fpage>181</fpage><lpage>189</lpage><pub-id pub-id-type="doi">10.1016/j.gie.2012.10.004</pub-id><pub-id pub-id-type="pmid">23245798</pub-id></element-citation><mixed-citation id="mc-CR20" publication-type="journal">Bick, B. L. <italic toggle="yes">et al.</italic> Stent-associated esophagorespiratory fistulas: Incidence and risk factors. <italic toggle="yes">Gastrointest. Endosc.</italic><bold>77</bold>(2), 181&#8211;189 (2013).<pub-id pub-id-type="pmid">23245798</pub-id><pub-id pub-id-type="doi">10.1016/j.gie.2012.10.004</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Choi</surname><given-names>MK</given-names></name><name name-style="western"><surname>Park</surname><given-names>YH</given-names></name><name name-style="western"><surname>Hong</surname><given-names>JY</given-names></name><name name-style="western"><surname>Park</surname><given-names>HC</given-names></name><name name-style="western"><surname>Ahn</surname><given-names>YC</given-names></name><name name-style="western"><surname>Kim</surname><given-names>K</given-names></name><name name-style="western"><surname>Shim</surname><given-names>YM</given-names></name><name name-style="western"><surname>Kang</surname><given-names>WK</given-names></name><name name-style="western"><surname>Park</surname><given-names>K</given-names></name><name name-style="western"><surname>Im</surname><given-names>YH</given-names></name></person-group><article-title>Clinical implications of esophagorespiratory fistulae in patients with esophageal squamous cell carcinoma (SCCA)</article-title><source>Med. Oncol.</source><year>2010</year><volume>27</volume><issue>4</issue><fpage>1234</fpage><lpage>1238</lpage><pub-id pub-id-type="doi">10.1007/s12032-009-9364-z</pub-id><pub-id pub-id-type="pmid">19924573</pub-id></element-citation><mixed-citation id="mc-CR21" publication-type="journal">Choi, M. K. <italic toggle="yes">et al.</italic> Clinical implications of esophagorespiratory fistulae in patients with esophageal squamous cell carcinoma (SCCA). <italic toggle="yes">Med. Oncol.</italic><bold>27</bold>(4), 1234&#8211;1238 (2010).<pub-id pub-id-type="pmid">19924573</pub-id><pub-id pub-id-type="doi">10.1007/s12032-009-9364-z</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sivaraman</surname><given-names>SK</given-names></name><name name-style="western"><surname>Drummond</surname><given-names>R</given-names></name></person-group><article-title>Radiation-induced aortoesophageal fistula: An unusual case of massive upper gastrointestinal bleeding</article-title><source>J. Emerg. Med.</source><year>2002</year><volume>23</volume><issue>2</issue><fpage>175</fpage><lpage>178</lpage><pub-id pub-id-type="doi">10.1016/S0736-4679(02)00488-2</pub-id><pub-id pub-id-type="pmid">12359287</pub-id></element-citation><mixed-citation id="mc-CR22" publication-type="journal">Sivaraman, S. K. &amp; Drummond, R. Radiation-induced aortoesophageal fistula: An unusual case of massive upper gastrointestinal bleeding. <italic toggle="yes">J. Emerg. Med.</italic><bold>23</bold>(2), 175&#8211;178 (2002).<pub-id pub-id-type="pmid">12359287</pub-id><pub-id pub-id-type="doi">10.1016/S0736-4679(02)00488-2</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L</given-names></name><name name-style="western"><surname>He</surname><given-names>B</given-names></name><name name-style="western"><surname>Li</surname><given-names>W</given-names></name><name name-style="western"><surname>Wen</surname><given-names>Q</given-names></name><name name-style="western"><surname>Wang</surname><given-names>S</given-names></name><name name-style="western"><surname>Sun</surname><given-names>X</given-names></name><name name-style="western"><surname>Meng</surname><given-names>X</given-names></name><name name-style="western"><surname>Yu</surname><given-names>J</given-names></name></person-group><article-title>Development and validation of a risk prediction model for radiotherapy-related esophageal fistula in esophageal cancer</article-title><source>Radiat. Oncol.</source><year>2019</year><volume>14</volume><issue>1</issue><fpage>181</fpage><pub-id pub-id-type="doi">10.1186/s13014-019-1385-y</pub-id><pub-id pub-id-type="pmid">31640802</pub-id><pub-id pub-id-type="pmcid">PMC6805370</pub-id></element-citation><mixed-citation id="mc-CR23" publication-type="journal">Xu, Y. <italic toggle="yes">et al.</italic> Development and validation of a risk prediction model for radiotherapy-related esophageal fistula in esophageal cancer. <italic toggle="yes">Radiat. Oncol.</italic><bold>14</bold>(1), 181 (2019).<pub-id pub-id-type="pmid">31640802</pub-id><pub-id pub-id-type="doi">10.1186/s13014-019-1385-y</pub-id><pub-id pub-id-type="pmcid">PMC6805370</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Morgan</surname><given-names>MA</given-names></name><name name-style="western"><surname>Twine</surname><given-names>CP</given-names></name><name name-style="western"><surname>Lewis</surname><given-names>WG</given-names></name><name name-style="western"><surname>Lambe</surname><given-names>R</given-names></name><name name-style="western"><surname>Oliphant</surname><given-names>HE</given-names></name><name name-style="western"><surname>Robinson</surname><given-names>M</given-names></name><name name-style="western"><surname>Crosby</surname><given-names>TD</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>SA</given-names></name></person-group><article-title>Prognostic significance of failure to cross esophageal tumors by endoluminal ultrasound</article-title><source>Dis. Esophagus</source><year>2008</year><volume>21</volume><issue>6</issue><fpage>508</fpage><lpage>513</lpage><pub-id pub-id-type="doi">10.1111/j.1442-2050.2008.00809.x</pub-id><pub-id pub-id-type="pmid">18430190</pub-id></element-citation><mixed-citation id="mc-CR24" publication-type="journal">Morgan, M. A. <italic toggle="yes">et al.</italic> Prognostic significance of failure to cross esophageal tumors by endoluminal ultrasound. <italic toggle="yes">Dis. Esophagus</italic><bold>21</bold>(6), 508&#8211;513 (2008).<pub-id pub-id-type="pmid">18430190</pub-id><pub-id pub-id-type="doi">10.1111/j.1442-2050.2008.00809.x</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kassis</surname><given-names>ES</given-names></name><name name-style="western"><surname>Kosinski</surname><given-names>AS</given-names></name><name name-style="western"><surname>Ross</surname><given-names>P</given-names><suffix>Jr</suffix></name><name name-style="western"><surname>Koppes</surname><given-names>KE</given-names></name><name name-style="western"><surname>Donahue</surname><given-names>JM</given-names></name><name name-style="western"><surname>Daniel</surname><given-names>VC</given-names></name></person-group><article-title>Predictors of anastomotic leak after esophagectomy: An analysis of the society of thoracic surgeons general thoracic database</article-title><source>Ann. Thorac. Surg.</source><year>2013</year><volume>96</volume><issue>6</issue><fpage>1919</fpage><lpage>1926</lpage><pub-id pub-id-type="doi">10.1016/j.athoracsur.2013.07.119</pub-id><pub-id pub-id-type="pmid">24075499</pub-id></element-citation><mixed-citation id="mc-CR25" publication-type="journal">Kassis, E. S. <italic toggle="yes">et al.</italic> Predictors of anastomotic leak after esophagectomy: An analysis of the society of thoracic surgeons general thoracic database. <italic toggle="yes">Ann. Thorac. Surg.</italic><bold>96</bold>(6), 1919&#8211;1926 (2013).<pub-id pub-id-type="pmid">24075499</pub-id><pub-id pub-id-type="doi">10.1016/j.athoracsur.2013.07.119</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liebermann-Meffert</surname><given-names>D</given-names></name></person-group><article-title>Anatomical basis for the approach and extent of surgical treatment of esophageal cancer</article-title><source>Dis. Esophagus</source><year>2001</year><volume>14</volume><issue>2</issue><fpage>81</fpage><lpage>84</lpage><pub-id pub-id-type="doi">10.1046/j.1442-2050.2001.00160.x</pub-id><pub-id pub-id-type="pmid">11553213</pub-id></element-citation><mixed-citation id="mc-CR26" publication-type="journal">Liebermann-Meffert, D. Anatomical basis for the approach and extent of surgical treatment of esophageal cancer. <italic toggle="yes">Dis. Esophagus</italic><bold>14</bold>(2), 81&#8211;84 (2001).<pub-id pub-id-type="pmid">11553213</pub-id><pub-id pub-id-type="doi">10.1046/j.1442-2050.2001.00160.x</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>X</given-names></name><name name-style="western"><surname>Jing</surname><given-names>J</given-names></name></person-group><article-title>Inflammation-related parameter serve as prognostic biomarker in esophageal squamous cell carcinoma</article-title><source>Front. Oncol.</source><year>2022</year><volume>12</volume><fpage>900305</fpage><pub-id pub-id-type="doi">10.3389/fonc.2022.900305</pub-id><pub-id pub-id-type="pmid">36338698</pub-id><pub-id pub-id-type="pmcid">PMC9634080</pub-id></element-citation><mixed-citation id="mc-CR27" publication-type="journal">Xu, X. &amp; Jing, J. Inflammation-related parameter serve as prognostic biomarker in esophageal squamous cell carcinoma. <italic toggle="yes">Front. Oncol.</italic><bold>12</bold>, 900305 (2022).<pub-id pub-id-type="pmid">36338698</pub-id><pub-id pub-id-type="doi">10.3389/fonc.2022.900305</pub-id><pub-id pub-id-type="pmcid">PMC9634080</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mantovani</surname><given-names>A</given-names></name><name name-style="western"><surname>Allavena</surname><given-names>P</given-names></name><name name-style="western"><surname>Sica</surname><given-names>A</given-names></name><name name-style="western"><surname>Balkwill</surname><given-names>F</given-names></name></person-group><article-title>Cancer-related inflammation</article-title><source>Nature</source><year>2008</year><volume>454</volume><issue>7203</issue><fpage>436</fpage><lpage>444</lpage><pub-id pub-id-type="doi">10.1038/nature07205</pub-id><pub-id pub-id-type="pmid">18650914</pub-id></element-citation><mixed-citation id="mc-CR28" publication-type="journal">Mantovani, A., Allavena, P., Sica, A. &amp; Balkwill, F. Cancer-related inflammation. <italic toggle="yes">Nature</italic><bold>454</bold>(7203), 436&#8211;444 (2008).<pub-id pub-id-type="pmid">18650914</pub-id><pub-id pub-id-type="doi">10.1038/nature07205</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barbetta</surname><given-names>A</given-names></name><name name-style="western"><surname>Nobel</surname><given-names>TB</given-names></name><name name-style="western"><surname>Sihag</surname><given-names>S</given-names></name><name name-style="western"><surname>Hsu</surname><given-names>M</given-names></name><name name-style="western"><surname>Tan</surname><given-names>KS</given-names></name><name name-style="western"><surname>Bains</surname><given-names>MS</given-names></name><name name-style="western"><surname>Isbell</surname><given-names>JM</given-names></name><name name-style="western"><surname>Janjigian</surname><given-names>YY</given-names></name><name name-style="western"><surname>Wu</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Bott</surname><given-names>MJ</given-names></name><etal/></person-group><article-title>Neutrophil to lymphocyte ratio as predictor of treatment response in esophageal squamous cell cancer</article-title><source>Ann. Thorac. Surg.</source><year>2018</year><volume>106</volume><issue>3</issue><fpage>864</fpage><lpage>871</lpage><pub-id pub-id-type="doi">10.1016/j.athoracsur.2018.04.007</pub-id><pub-id pub-id-type="pmid">29738752</pub-id><pub-id pub-id-type="pmcid">PMC6117834</pub-id></element-citation><mixed-citation id="mc-CR29" publication-type="journal">Barbetta, A. <italic toggle="yes">et al.</italic> Neutrophil to lymphocyte ratio as predictor of treatment response in esophageal squamous cell cancer. <italic toggle="yes">Ann. Thorac. Surg.</italic><bold>106</bold>(3), 864&#8211;871 (2018).<pub-id pub-id-type="pmid">29738752</pub-id><pub-id pub-id-type="doi">10.1016/j.athoracsur.2018.04.007</pub-id><pub-id pub-id-type="pmcid">PMC6117834</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L</given-names></name></person-group><article-title>The clinical use of pretreatment NLR, PLR, and LMR in patients with esophageal squamous cell carcinoma: Evidence from a meta-analysis</article-title><source>Cancer Manag. Res.</source><year>2018</year><volume>10</volume><fpage>6167</fpage><lpage>6179</lpage><pub-id pub-id-type="doi">10.2147/CMAR.S171035</pub-id><pub-id pub-id-type="pmid">30538564</pub-id><pub-id pub-id-type="pmcid">PMC6257133</pub-id></element-citation><mixed-citation id="mc-CR30" publication-type="journal">Sun, Y. &amp; Zhang, L. The clinical use of pretreatment NLR, PLR, and LMR in patients with esophageal squamous cell carcinoma: Evidence from a meta-analysis. <italic toggle="yes">Cancer Manag. Res.</italic><bold>10</bold>, 6167&#8211;6179 (2018).<pub-id pub-id-type="pmid">30538564</pub-id><pub-id pub-id-type="doi">10.2147/CMAR.S171035</pub-id><pub-id pub-id-type="pmcid">PMC6257133</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cai</surname><given-names>G</given-names></name><name name-style="western"><surname>Yu</surname><given-names>J</given-names></name><name name-style="western"><surname>Meng</surname><given-names>X</given-names></name></person-group><article-title>Predicting prognosis and adverse events by hematologic markers in patients with locally advanced esophageal squamous cell carcinoma treated with neoadjuvant chemoradiotherapy</article-title><source>Cancer Manag. Res.</source><year>2020</year><volume>12</volume><fpage>8497</fpage><lpage>8507</lpage><pub-id pub-id-type="doi">10.2147/CMAR.S257058</pub-id><pub-id pub-id-type="pmid">33061564</pub-id><pub-id pub-id-type="pmcid">PMC7519412</pub-id></element-citation><mixed-citation id="mc-CR31" publication-type="journal">Cai, G., Yu, J. &amp; Meng, X. Predicting prognosis and adverse events by hematologic markers in patients with locally advanced esophageal squamous cell carcinoma treated with neoadjuvant chemoradiotherapy. <italic toggle="yes">Cancer Manag. Res.</italic><bold>12</bold>, 8497&#8211;8507 (2020).<pub-id pub-id-type="pmid">33061564</pub-id><pub-id pub-id-type="doi">10.2147/CMAR.S257058</pub-id><pub-id pub-id-type="pmcid">PMC7519412</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Han</surname><given-names>D</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>J</given-names></name><name name-style="western"><surname>Lei</surname><given-names>T</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>T</given-names></name><name name-style="western"><surname>Wei</surname><given-names>H</given-names></name><name name-style="western"><surname>Guan</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>W</given-names></name><etal/></person-group><article-title>Platelet-to-lymphocyte ratio is an independent predictor of chemoradiotherapy-related esophageal fistula in esophageal cancer patients</article-title><source>Ann. Transl. Med.</source><year>2020</year><volume>8</volume><issue>18</issue><fpage>1163</fpage><pub-id pub-id-type="doi">10.21037/atm-20-4053</pub-id><pub-id pub-id-type="pmid">33241012</pub-id><pub-id pub-id-type="pmcid">PMC7576074</pub-id></element-citation><mixed-citation id="mc-CR32" publication-type="journal">Han, D. <italic toggle="yes">et al.</italic> Platelet-to-lymphocyte ratio is an independent predictor of chemoradiotherapy-related esophageal fistula in esophageal cancer patients. <italic toggle="yes">Ann. Transl. Med.</italic><bold>8</bold>(18), 1163 (2020).<pub-id pub-id-type="pmid">33241012</pub-id><pub-id pub-id-type="doi">10.21037/atm-20-4053</pub-id><pub-id pub-id-type="pmcid">PMC7576074</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liang</surname><given-names>W</given-names></name><name name-style="western"><surname>Ferrara</surname><given-names>N</given-names></name></person-group><article-title>The complex role of neutrophils in tumor angiogenesis and metastasis</article-title><source>Cancer Immunol. Res.</source><year>2016</year><volume>4</volume><issue>2</issue><fpage>83</fpage><lpage>91</lpage><pub-id pub-id-type="doi">10.1158/2326-6066.CIR-15-0313</pub-id><pub-id pub-id-type="pmid">26839309</pub-id></element-citation><mixed-citation id="mc-CR33" publication-type="journal">Liang, W. &amp; Ferrara, N. The complex role of neutrophils in tumor angiogenesis and metastasis. <italic toggle="yes">Cancer Immunol. Res.</italic><bold>4</bold>(2), 83&#8211;91 (2016).<pub-id pub-id-type="pmid">26839309</pub-id><pub-id pub-id-type="doi">10.1158/2326-6066.CIR-15-0313</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gao</surname><given-names>QF</given-names></name><name name-style="western"><surname>Qiu</surname><given-names>JC</given-names></name><name name-style="western"><surname>Huang</surname><given-names>XH</given-names></name><name name-style="western"><surname>Xu</surname><given-names>YM</given-names></name><name name-style="western"><surname>Li</surname><given-names>SQ</given-names></name><name name-style="western"><surname>Sun</surname><given-names>F</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J</given-names></name><name name-style="western"><surname>Yang</surname><given-names>WM</given-names></name><name name-style="western"><surname>Min</surname><given-names>QH</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>YH</given-names></name><etal/></person-group><article-title>The predictive and prognostic role of a novel ADS score in esophageal squamous cell carcinoma patients undergoing esophagectomy</article-title><source>Cancer Cell Int.</source><year>2018</year><volume>18</volume><fpage>153</fpage><pub-id pub-id-type="doi">10.1186/s12935-018-0648-2</pub-id><pub-id pub-id-type="pmid">30305803</pub-id><pub-id pub-id-type="pmcid">PMC6171189</pub-id></element-citation><mixed-citation id="mc-CR34" publication-type="journal">Gao, Q. F. <italic toggle="yes">et al.</italic> The predictive and prognostic role of a novel ADS score in esophageal squamous cell carcinoma patients undergoing esophagectomy. <italic toggle="yes">Cancer Cell Int.</italic><bold>18</bold>, 153 (2018).<pub-id pub-id-type="pmid">30305803</pub-id><pub-id pub-id-type="doi">10.1186/s12935-018-0648-2</pub-id><pub-id pub-id-type="pmcid">PMC6171189</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>CC</given-names></name><name name-style="western"><surname>Chen</surname><given-names>CY</given-names></name><name name-style="western"><surname>Chou</surname><given-names>YH</given-names></name><name name-style="western"><surname>Huang</surname><given-names>CJ</given-names></name><name name-style="western"><surname>Ku</surname><given-names>HY</given-names></name><name name-style="western"><surname>Lin</surname><given-names>YC</given-names></name><name name-style="western"><surname>Chien</surname><given-names>CR</given-names></name></person-group><article-title>High vs low radiotherapy dose in locally advanced esophageal squamous cell carcinoma patients treated with neoadjuvant concurrent chemoradiotherapy: An endemic area population-based study</article-title><source>Discov. Oncol.</source><year>2022</year><volume>13</volume><issue>1</issue><fpage>130</fpage><pub-id pub-id-type="doi">10.1007/s12672-022-00594-y</pub-id><pub-id pub-id-type="pmid">36434304</pub-id><pub-id pub-id-type="pmcid">PMC9700542</pub-id></element-citation><mixed-citation id="mc-CR35" publication-type="journal">Li, C. C. <italic toggle="yes">et al.</italic> High vs low radiotherapy dose in locally advanced esophageal squamous cell carcinoma patients treated with neoadjuvant concurrent chemoradiotherapy: An endemic area population-based study. <italic toggle="yes">Discov. Oncol.</italic><bold>13</bold>(1), 130 (2022).<pub-id pub-id-type="pmid">36434304</pub-id><pub-id pub-id-type="doi">10.1007/s12672-022-00594-y</pub-id><pub-id pub-id-type="pmcid">PMC9700542</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Balazs</surname><given-names>A</given-names></name><name name-style="western"><surname>Galambos</surname><given-names>Z</given-names></name><name name-style="western"><surname>Kupcsulik</surname><given-names>PK</given-names></name></person-group><article-title>Characteristics of esophagorespiratory fistulas resulting from esophageal cancers: A single-center study on 243 cases in a 20-year period</article-title><source>World J. Surg.</source><year>2009</year><volume>33</volume><issue>5</issue><fpage>994</fpage><lpage>1001</lpage><pub-id pub-id-type="doi">10.1007/s00268-009-9988-3</pub-id><pub-id pub-id-type="pmid">19288038</pub-id></element-citation><mixed-citation id="mc-CR36" publication-type="journal">Balazs, A., Galambos, Z. &amp; Kupcsulik, P. K. Characteristics of esophagorespiratory fistulas resulting from esophageal cancers: A single-center study on 243 cases in a 20-year period. <italic toggle="yes">World J. Surg.</italic><bold>33</bold>(5), 994&#8211;1001 (2009).<pub-id pub-id-type="pmid">19288038</pub-id><pub-id pub-id-type="doi">10.1007/s00268-009-9988-3</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shin</surname><given-names>JH</given-names></name><name name-style="western"><surname>Song</surname><given-names>HY</given-names></name><name name-style="western"><surname>Ko</surname><given-names>GY</given-names></name><name name-style="western"><surname>Lim</surname><given-names>JO</given-names></name><name name-style="western"><surname>Yoon</surname><given-names>HK</given-names></name><name name-style="western"><surname>Sung</surname><given-names>KB</given-names></name></person-group><article-title>Esophagorespiratory fistula: Long-term results of palliative treatment with covered expandable metallic stents in 61 patients</article-title><source>Radiology</source><year>2004</year><volume>232</volume><issue>1</issue><fpage>252</fpage><lpage>259</lpage><pub-id pub-id-type="doi">10.1148/radiol.2321030733</pub-id><pub-id pub-id-type="pmid">15166325</pub-id></element-citation><mixed-citation id="mc-CR37" publication-type="journal">Shin, J. H. <italic toggle="yes">et al.</italic> Esophagorespiratory fistula: Long-term results of palliative treatment with covered expandable metallic stents in 61 patients. <italic toggle="yes">Radiology</italic><bold>232</bold>(1), 252&#8211;259 (2004).<pub-id pub-id-type="pmid">15166325</pub-id><pub-id pub-id-type="doi">10.1148/radiol.2321030733</pub-id></mixed-citation></citation-alternatives></ref></ref-list></back></article></pmc-articleset>